Acrivon Therapeutics Inc. (ACRV), a clinical stage biopharmaceutical company, has announced a $130 million private placement financing.
Through the private investment in public equity ("PIPE") financing with certain existing and new accredited investors, the company will issue and sell an aggregate of 8.235 million shares of its common stock at a price of $8.50 per share, and pre-funded warrants to purchase up to an aggregate of 7.06 million shares of common stock at a purchase price of $8.499 per pre-funded warrant.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com